Creating new treatments for synthetic opioid overdose
Development of Agents for Synthetic Opioid Overdose
This study is looking for better ways to help people who have overdosed on synthetic opioids like fentanyl, by testing new medications that can work longer and stronger than the ones we currently use, to keep everyone safer in emergencies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10672919 on NIH RePORTER |
What this research studies
This research focuses on developing more effective agents to counteract the effects of synthetic opioids like fentanyl, which can cause life-threatening respiratory depression. The approach involves identifying and testing new opioid antagonists that are more potent and longer-acting than current options like naloxone. By improving the reversal of opioid overdose, the research aims to enhance safety for both patients and first responders in emergency situations. The methodology includes laboratory testing and potential clinical applications to ensure these new agents can be safely used in real-world scenarios.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk of opioid overdose, such as those using synthetic opioids for pain management.
Not a fit: Patients who do not use synthetic opioids or are not at risk of overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for opioid overdose, potentially saving lives.
How similar studies have performed: Previous research has shown promise in developing new opioid antagonists, but this specific approach is novel and aims to address significant gaps in current treatment options.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Prisinzano, Thomas Edward — University of Kentucky
- Study coordinator: Prisinzano, Thomas Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.